


Frame S., MacKay R.H., Hogben M., Connolly C., Anderson S., Fleming I.N., Davis S., Blake D., Green S. Exploiting the unique mechanism of action of sapacitabine (CYC682) to obtain synergy with other therapeutic agents for clinical use in Acute Myeloid Leukemia, 14th Congress of the European Hematology Association (EHA), June 4-7, 2009, Berlin, Germany, Abstract 0761.

Garcia-Manero G., Luger S., Venugopal P., Maness L., Wetzler M., Coutre S., Stock W., Borthakur1 G., Chiao J.H., & Kantarjian H. A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS, J Clin Oncol 27:15s, 2009 (suppl; abstr 7021).


Synergistic interactions between sapacitabine (CYC682) and inhibitors of either histone deacetylase or methyltransferase in Acute Myeloid Leukemia cell lines. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract 4552.


The nucleoside analogue sapacitabine (CYC682) synergises with histone deacetylase inhibitors in multiple tumour types. Poster. 20th EORTC-NCI-AACR Meeting. EJC Supplement, 2008 6 (12);150


The basis of cell sensitivity to Aurora A/B inhibitors. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008, Apr 12-16; San Diego, CA, Abstract #651.


McClue, S., and Stuart, I., Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos. 2008 36:561


Walker, R.G., Grant K.M., Thomson, G and Mottram, J.C. Leishmania CRK3:CYC6 cyclin-dependent kinase as a drug target. 2007 Molecular Parasitology meeting XVII, Woods Hole, Boston, USA


Chassagnole C.; Jackson RC; Hussain N; Bashir L; Derow C; Savin J; Fell DA. Using a mammalian cell cycle simulation to interpret differential kinase inhibition in anti-tumour pharmaceutical development. *BioSystems* (2006); 83: 91-97.


Kontopidis G.; McInnes C.; Pandalaneni S.R.; McNae I.; Gibson D.; Mezna M.; Thomas M.; Wood G.; Wang S.; Walkinshaw M.D.; Fischer P.M. Differential Binding of Inhibitors to Active and Inactive CDK2 Provides Insights for Drug Design. Chemistry & Biology, February 2006, 13, 201-211


McInnes, C.; Mezna M.; Fischer P. M.; Progress in the Discovery of Polo-like Kinase Inhibitors. Current topics in Medicinal Chemistry 2005: 5:181.


McInnes C., Second Annual Protein Kinases Conference: Addressing the challenges across the Kinome; Kinase drug discovery and disease biology; *IDrugs* 2003: 6(12):1135.

McInnes C., Second Annual Protein Kinases Conference: Addressing the challenges across the Kinome; Clinical Update, new therapies and new technologies; *IDrugs* 2003: 6(12):1138.


Raynaud F.L, Nutley B.P., Goddard P.M., Fischer P., McClue S., Lane D., Workman P. Cassette dosing is a valid approach to evaluate the pharmacokinetics of trisubstituted purines such as Olomoucine, Roscovitine and Bohemine. Br. J. Cancer Res. 2000:83(Suppl. 1): 68.


